newsfilter
← Latest News
GlobeNewswire·

Evaxion announces business update and second quarter 2026 financial results

  • Evaxion A/S announced Q2 2026 financial results & a business update highlighting progress toward 2026 strategic milestones.
  • The company will present three-year clinical data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 in October.
  • New data for off-the-shelf vaccine EVX-04 (AML) was presented at the EHA 2026 Congress, showing complete expression in human cells & effective immune responses.
  • Regulatory filing for clinical testing of EVX-04 is expected before the end of 2026.
  • Pipeline expansion includes EVX-05, a novel off-the-shelf vaccine for glioblastoma targeting shared endogenous retrovirus antigens.
  • New data for CMV vaccine candidate EVX-V1 was presented at the International Herpesvirus Workshop 2026, demonstrating potential to control infection, latency, & reactivation.
  • Evaxion won the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform.
  • Net loss for Q2 2026 was $3.7 million, compared to $3.6 million in Q1 2026 & $4.8 million in Q2 2025.
  • R&D expenses were $2.3 million for Q2 2026, while General & Administrative expenses were $1.5 million.
  • Cash & cash equivalents totaled $14.0 million as of June 30, 2026, extending the cash runway into the second half of 2027.
  • Total equity was $9.5 million as of June 30, 2026, reflecting a net loss of $7.4 million for the first six months of the year.
  • Executive management hosted a conference call & webcast on August 20, 2026, to discuss results & field questions.
  • The company remains active in partnership discussions to strengthen its AI platform & pipeline value.
  • Future R&D programs for autoimmune diseases are expected to be launched in the second half of 2026.